Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback